Dr. David Nanus, MD – New York, NY
Overview of Dr. Nanus
I am the Director of New York Presbyterian Hospital - Weill Cornell Medicine Healthcare Systems Cancer Program and the Associate Director for Clinical Services in the Meyer Cancer Center at Weill Cornell Medicine. I was Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College – New York Presbyterian Hospital for a5 years from 2004-2019. I am also the Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine and Professor of Medicine and Urology. I completed my clinical training in Medicine at Albert Einstein College of Medicine followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center, and research training at the Sloan Kettering Institute. I joined the faculty at Memorial Sloan Kettering Cancer Center in 1989 as a physician scientist and was recruited to the full-time faculty of Weill Cornell Medical College in 1998. My clinical focus is the treatment and care of patients with genitourinary (GU) cancers, and I am actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of grants and clinical research trials that incorporate novel targeted therapies for patients, working closely with physicians and scientists.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1985 - 1989
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1983 - 1985
University of Wisconsin Hospitals and ClinicsInternship, Internal Medicine, 1982 - 1983
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1982
University of Illinois at Urbana-ChampaignB.S., 1974 - 1978
Certifications & Licensure
Awards, Honors, & Recognition
- Member American Association of Physicians, 2005
- Top Doctors for Cancer Newsweek Magazine, 2015
- Top Ranked U.S. Executive National Council of American Executives, 2014
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Halabi, S., Guo, S., Park, J., George, D., McDonnell, D., Norris, J., Lu, C., Luo, J., Armstrong, A., Nanus, D., Antonarakis, E., Danila, D., Szmulewitz, R.> ;Clinical Cancer Research. 2024 Jan 18- 1 citations
NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.
Jaclyn M Kubala, Kristian B Laursen, Ryan Schreiner, Ryan M Williams, Johannes C van der Mijn, Michael J Crowley, Nigel P Mongan, David M Nanus, Daniel A Heller, Lorra...> ;Cancer Biology & Therapy. 2023 Dec 31 Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study o...
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, Michael Sun, Judith Stangl-Kremser, Mahelia Bissassar, Shankar Vallabhajosula, Jones T Nauseef, Cora N Sternberg, Ana...> ;Journal of Clinical Oncology. 2023 Nov 3- Join now to see all
Journal Articles
Kidney cancer: novel targets in altered tumour metabolism
Minton DR and Nanus DM, Nature Rev Urol, 1/1/2015CANCER Cancer therapies that are gone with the Wnt
Nanus DM and Giannakakou P, Science, 1/1/2015The tale of two hypoxia-inducible factors in renal cell carcinoma
Nanus DM and Gudas LJ, Eur Urol, 1/1/2015- Join now to see all
Books/Book Chapters
Nuclear Medicine Therapy: Principles and Clinical Applications
Chapter: Radioimmunotherapy of prostate carcinoma.
Goldsmith SJ, Tagawa ST, Vallabhajosula S, Nikolopoulou A, Lipai I, Nanus DM, Bander NHEditors: Aktolun C and Goldsmith SJ.Springer Science+Business Media2013ASCO-SEP Medical Oncology Self- Evaluation Program Version III
Chapter: Genitourinary Cancers
Nanus DM and Milowsky MIEditors: Moore A.American Society of Clinical Oncology2013Targeted Therapies for Renal Cell Carcinoma
Chapter: Chemotherapy in metastatic RCC: A targeted approach in non-clear-cell and sarcomatoid/rapidly progressive RCC
Diamond E, Akhtar NH, Tagawa ST, Nanus DMEditors: Bukowski R.Future Science Group2012- Join now to see all
Lectures
Taxanes: Novel Combinations and Clinical States
Chicago, IL - 1/29/2015Circulating Tumor Cells in the Microenvironment
Lawrence Livermore National Laboratory, CA - 1/27/2015Advances and clinical trial opportunities in immunotherapy for GU cancers.
Las Vegas, NV - 1/13/2015- Join now to see all
Other
Beyond the Abstract - Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.
Beltran H, Nanus DM, Tagawa ST, UroToday.com
1/30/2010Recent advances in management of renal cancer.
Shah JH, Nanus DM, f1000 Medicine Reports
1/1/2009
Press Mentions
How to Find Support When You Have Metastatic Kidney CancerApril 25th, 2023
Department of Defense Awards Weill Cornell Medicine New Grant for Kidney Cancer ResearchSeptember 1st, 2022
Cancers Leading Cause of Premature Death in Brooklyn: NY-Presbyterian PhysiciansAugust 7th, 2019
- Join now to see all
Grant Support
- Phase II Trial Of 177lu-J591 In Metastatic, Androgen-Independent Prostate CancerNational Center For Research Resources2007
- Phase I Trial Of ATRA-IV &Depakote In PTS W/Advanced Solid Tumor MalignanciesNational Center For Research Resources2005–2006
- Modulation Of Retinoic Acid Action In Renal CancerNational Cancer Institute2001–2005
- Neutral Endopeptidase Inactivation In Advanced ProstateNational Cancer Institute1998–2005
- Phase I 111-Indium Radiolabeled MAB Huj591/ Metastatic Solid TumorsNational Center For Research Resources2004
- Chemoprevention Of Prostate Cancer With FinasterideNational Center For Research Resources2004
- Anti Tumor Therapies For Genioturinary MalignanciesNational Cancer Institute2000–2004
- Alpha Interferon Resistance In Renal CancerNational Cancer Institute1994–1996
- Analysis Of Alpha-Interferon Resistance In Renal CancerNational Cancer Institute1992–1993
Professional Memberships
Hospital Affiliations
Insurance Accepted
Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Choice
First Health PPO
GHI PPO
Great West PPO
Health Net Oregon PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO- Please verify your coverage with the provider's office directly when scheduling an appointment
